Indication
Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

Medicine details

Medicine name:
semaglutide (Ozempic)
SMC ID:
SMC2092
Pharmaceutical company
Novo Nordisk Ltd
BNF chapter
Endocrine system
Submission type
Full submission
Status
Advice due date:
10 December 2018
SMC meeting date:
06 November 2018
Patient group submission deadline:
01 October 2018